Eli Lilly Retatrutide Achieves Significant Weight Loss in Phase 3 Trial Eli Lilly's retatrutide met primary endpoint. Phase 3 obesity trial showed high efficacy. Patients lost approximately 25% body weight. This sets a new benchmark for weight loss. Eli Lilly announced positive Phase 3 results for retatrutide. The triple-G agonist demonstrated remarkable efficacy in its obesity trial. Patients achieved an average weight reduction of approximately 25%. This metric surpassed expectations, confirming retatrutide's potential as a leading metabolic therapy. The trial successfully met its primary endpoint. This positive outcome paves the way for regulatory submissions. Eli Lilly will likely pursue accelerated approval pathways with the FDA and EMA. Such substantial efficacy data supports a strong New Drug Application (NDA). The FDA's 21 CFR Part 314 outlines requirements for drug approval. EMA will also review the data for marketing authorization. Next steps involve compiling comprehensive submission packages. Retatrutide's success intensifies competition in the obesity market. It positions Lilly ahead of rivals like Novo Nordisk's Wegovy. This drug could redefine treatment standards. The strong results solidify Lilly's leadership in metabolic diseases. Expect regulatory filings by late 2026, potentially leading to market entry in 2027.